Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs
Speedy COVID-19 Strategies Will Be Applied In Cancer R&D
Executive Summary
Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.
You may also be interested in...
Seagen And Nurix Hope To Pioneer A New Class Of Degrader-Antibody Conjugates
The two drug developers announced a collaboration to develop and commercialize multiple cancer programs. Nurix will receive $60m up front.
Seagen’s Tukysa Trial With Kadcyla Supports ADC Combination, But Safety Paramount
Results of the HER2CLIMB-02 study supported Tukysa combinations with antibody-drug conjugates. However, treatment discontinuations drew caution.
Pfizer Cost Improvement Program Depends On COVID Outlook
If COVID-19 product sales don’t meet assumptions this fall, the company said it will consider a cost reduction program to better align costs with future revenue projections.